Business
In Ovations Holdings, Inc. Enters Into Sales and Marketing Agreement With Regulon, Inc. Expanding Its Cancer Detection Offerings to Include Cancer Treatment Solutions
In Ovations Holdings, Inc. Enters Into Sales and Marketing Agreement With Regulon, Inc. Expanding Its Cancer Detection Offerings to Include Cancer Treatment Solutions.
About this update from In Ovations Holdings Inc
[{"type":"text","content":"\n \n \n In Ovations Holdings, Inc. Enters Into Sales and Marketing Agreement With Regulon, Inc. Expanding Its Cancer Detection Offerings to Include Cancer Treatment Solutions\n \n \nIn Ovations Holdings, Inc. Enters Into Sales and Marketing Agreement With Regulon, Inc. Expanding Its Cancer Detection Offerings to Include Cancer Treatment Solutions\n \n DORAL, FL--(Marketwired - Dec 8, 2014) - In Ovations Holdings, Inc. (OTC PINK: INOH) has concluded negotiations and due diligence and has entered into a sales and marketing agreement with Regulon, Inc. (\"Regulon\") for the marketing and sale of Regulon's anti-cancer therapies. The parties will leverage INOH's access to markets including the Caribbean in order to broaden the awareness and sale of their cancer detection and treatment products. The global cancer market was $75-80 billion in 2013. Sales of platinum-based chemotherapy drugs (cisplatin, carboplatin, oxaliplatin) were $2.6 bn (in seven major pharmaceutical markets) in 2008.\n Regulon designs and produces the following anti-cancer drugs: LipoPlatin™, LipoXal™, LipoVil-12™. Regulon has developed a unique liposome encapsulation technology applicable to drugs such as cisplatin, a cytotoxic agent, small molecules, peptides, proteins and viruses aiming at improving human lives and reducing the side effects of chemotherapy known to exacerbate the quality of life of cancer patients. Regulon is currently engaged in active sales.\n Recent studies showed that platinum-based chemotherapy drugs share is growing. The platinum drug market is anticipated to increase tremendously after cisplatin, a cytotoxin agent, is replaced by Regulon's LipoPlatin™. Regulon is a private biopharmaceutical company committed to the discovery and development of nano-pharmaceutics in oncology which has raised over $30,000,000 in the private marketplace in countries including Greece, Cyprus, Austria, Turkey, Korea, Brazil, Taiwan, Israel, and Lebanon. \n Teni Boulikas, PhD., President and CEO of Regulon, stated: \"After establishing a solid base in Europe and breaking into the Asian market, we are pleased to partner with INOH. We view this relationship as symbiotic, offering INOH's clients cancer solutions from detection to treatment. We look forward to the introduction of Regulon's products to the...